Literature DB >> 26321090

KIR3DL1 interaction with HLA-B27 is altered by ankylosing spondylitis associated ERAP1 and enhanced by MHC class I cross-linking.

Hasan Abdullah1, Zhenbo Zhang2, Kirby Yee3, Nigil Haroon4.   

Abstract

Ankylosing spondylitis (AS) is a chronic, inflammatory arthritis of the spine and peripheral joints linked to the antigen presenting molecule HLA-B27. The risk of AS is increased in patients possessing endoplasmic reticulum aminopeptidase-1 (ERAP1) polymorphisms rs30187 and rs27044 encoding amino acid changes K528R and Q730E, respectively. Dysfunction of ERAP1 is hypothesized to cause changes in expression of HLA-B27 classical (pHLA) and non-classical (FHC) conformers on antigen presenting cells (APCs), which interact with the natural killer (NK) cell receptor KIR3DL1. Dysregulation of this pathway may be pathogenic in AS. APC cell lines expressing HLA-B27 were found to inhibit cytokine production in KIR3DL1+ NK cells due to decreased APC-NK cell adhesion, and possibly activation of receptor down-regulation. Blocking pHLA and FHC reveals that both conformers inhibit cytokine production through KIR3DL1. KIR3DL1 affinity and HLA-B27 surface expression studies suggest that ERAP1 R528 and E730 expression protects from AS by generating sub-optimal pHLA, causing reduced KIR3DL1 affinity and weaker cytokine inhibition. Secondarily we observed that KIR3DL1 binding to C1R-B27 APCs is enhanced by blocking pHLA, but not FHC, raising the possibility that antibody mediated HLA-B27 cross-linking may be important in enhancing KIR3DL1+ NK cell function. This study establishes the role of both FHC and pHLA in modulating NK cell cytokine secretion and adhesion functions by interacting with KIR3DL1. This interaction varies depending on the AS association status of the ERAP1 variant expressed in APCs. Additionally antibody cross-linking of HLA-B27 enhances KIR3DL1 binding and as such could be an important pathogenic mechanism in AS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26321090

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  4 in total

Review 1.  Pathogenesis of ankylosing spondylitis - recent advances and future directions.

Authors:  Vidya Ranganathan; Eric Gracey; Matthew A Brown; Robert D Inman; Nigil Haroon
Journal:  Nat Rev Rheumatol       Date:  2017-04-27       Impact factor: 20.543

Review 2.  'MHC-I-opathy'-unified concept for spondyloarthritis and Behçet disease.

Authors:  Dennis McGonagle; Sibel Zehra Aydin; Ahmet Gül; Alfred Mahr; Haner Direskeneli
Journal:  Nat Rev Rheumatol       Date:  2015-11-03       Impact factor: 20.543

3.  Global Proteomic Analyses Reveals Abnormal Immune Regulation in Patients With New Onset Ankylosing Spondylitis.

Authors:  Zongchao Yu; Xiaoping Hong; Xiaoli Zhang; Fengping Zheng; Fanna Liu; Huixuan Xu; Chengxin Zhu; Wanxia Cai; Dongzhou Liu; Lianghong Yin; Bo Hu; Donge Tang; Yong Dai
Journal:  Front Immunol       Date:  2022-03-17       Impact factor: 7.561

Review 4.  Targeting inflammatory pathways in axial spondyloarthritis.

Authors:  Daniel E Furst; James S Louie
Journal:  Arthritis Res Ther       Date:  2019-06-04       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.